Adaptive trial for severe pneumonia care in intensive care
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests ways to improve treatment for adults with severe pneumonia that lands them in the ICU, adjusting the plan as results come in. It may help your care team find better treatments for lung infection and breathing/heart support needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older) admitted to the ICU for severe pneumonia within 48 hours of arriving at the hospital
- You likely have symptoms of a lower lung infection, plus a chest scan showing a new pneumonia finding
- Within 48 hours after ICU admission, you need one or more organ supports such as breathing help (machine breathing or non-invasive breathing) or medicines to support blood pressure/heart function
- This pneumonia must not be healthcare-related (not from a recent hospital stay in the last 30 days, and not from a nursing home/long-term care)
- You have not joined this REMAP study in the last 90 days
- You are not expected to be discharged from the hospital today or tomorrow (applies to the COVID-related part of the trial)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different treatments for serious lung infections in people who are already in the hospital. It may help doctors learn which treatment works best for recovery and survival when pneumonia-like illness is suspected.
This platform trial studies which treatment works best for adults with sudden, severe breathing failure needing oxygen or a breathing machine in the ICU. It may help patients by matching them to the most appropriate treatment strategy and tracking outcomes to improve care.
This trial tests a new drug called SR1375 for adults with severe community-acquired pneumonia (a lung infection) who are not improving with standard antibiotics. It may help reduce inflammation and speed up recovery.
This trial tests a new medication called OPT101 for people hospitalized with pneumonia and sepsis (a severe infection that affects the whole body). The drug may help reduce inflammation and improve oxygen levels. The study focuses on those who need extra oxygen but are not yet on a breathing machine.
This trial tests whether adding an experimental herbal medicine (NRICM102) to standard antibiotics can help adults hospitalized with community-acquired pneumonia recover faster. It is a phase 2 study, meaning the treatment is still being tested for safety and effectiveness.
This trial tests whether adding anti-inflammatory medicine (steroids) to usual care helps people with severe pneumonia recover faster. It only includes patients who are seriously ill in the ICU, and the goal is to find the best way to reduce lung inflammation and improve outcomes.
Hear when a new Community-acquired Pneumonia, Influenza, COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.